[{"bbox": [91, 99, 370, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [99, 170, 1560, 233], "category": "List-item", "text": "4) Our Company shall comply with the requirements of SEBI Listing Regulations, 2015 in relation to the disclosure and monitoring of the utilization of the proceeds of the Issue."}, {"bbox": [99, 233, 1562, 298], "category": "List-item", "text": "5) Our Company shall not have recourse to the Issue Proceeds until the approval for listing and trading of the Equity Shares from the Stock Exchange where listing is sought has been received."}, {"bbox": [99, 298, 1562, 363], "category": "List-item", "text": "6) The Book Running Lead Managers undertakes that the complaints or comments received in respect of the Issue shall be attended by our Company expeditiously and satisfactorily."}, {"bbox": [91, 393, 805, 426], "category": "Section-header", "text": "## Equity Shares in Dematerialized Form with NSDL or CDSL"}, {"bbox": [91, 458, 1560, 523], "category": "Text", "text": "To enable all shareholders of our Company to have their shareholding in electronic form, the Company has signed the following tripartite agreements with the Depositories and the Registrar and Share Transfer Agent:"}, {"bbox": [91, 554, 1349, 587], "category": "List-item", "text": "* Tripartite Agreement dated December 31, 2024 between NSDL, the Company and the Registrar to the Issue;"}, {"bbox": [91, 589, 1306, 622], "category": "List-item", "text": "* Tripartite Agreement dated March 05, 2025 between CDSL, the Company and the Registrar to the Issue;"}, {"bbox": [91, 652, 771, 686], "category": "Text", "text": "The Company's equity shares bear an ISIN: INE1G2W01011"}]